EPS for Mersana Therapeutics, Inc. (MRSN) Expected At $-0.50; Ulysses Management Lowered Cisco Systems (Call) (CSCO) Holding By $462,000

January 14, 2018 - By Dolores Ford

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.50 EPS on February, 8.After having $-0.35 EPS previously, Mersana Therapeutics, Inc.’s analysts see 42.86% EPS growth. The stock decreased 2.89% or $0.46 during the last trading session, reaching $15.44. About 40,813 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Ulysses Management Llc decreased Cisco Systems Inc (Call) (CSCO) stake by 28% reported in 2017Q3 SEC filing. Ulysses Management Llc sold 14,000 shares as Cisco Systems Inc (Call) (CSCO)’s stock declined 7.50%. The Ulysses Management Llc holds 36,000 shares with $1.21 million value, down from 50,000 last quarter. Cisco Systems Inc (Call) now has $202.05B valuation. The stock increased 1.92% or $0.77 during the last trading session, reaching $40.87. About 23.77M shares traded or 19.09% up from the average. Cisco Systems, Inc. (NASDAQ:CSCO) has risen 13.20% since January 14, 2017 and is uptrending. It has underperformed by 3.50% the S&P500.

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, July 24 by J.P. Morgan. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) earned “Buy” rating by Cowen & Co on Monday, July 24. The firm earned “Buy” rating on Monday, July 24 by Leerink Swann.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $351.31 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

Among 37 analysts covering Cisco Systems Inc. (NASDAQ:CSCO), 24 have Buy rating, 0 Sell and 13 Hold. Therefore 65% are positive. Cisco Systems Inc. had 135 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital on Thursday, November 16 with “Buy”. The rating was maintained by JP Morgan on Thursday, May 19 with “Neutral”. Drexel Hamilton maintained Cisco Systems, Inc. (NASDAQ:CSCO) rating on Friday, June 23. Drexel Hamilton has “Buy” rating and $3900 target. Robert W. Baird maintained the shares of CSCO in report on Monday, August 7 with “Buy” rating. The stock of Cisco Systems, Inc. (NASDAQ:CSCO) earned “Equal-Weight” rating by Morgan Stanley on Thursday, August 18. The stock of Cisco Systems, Inc. (NASDAQ:CSCO) has “Hold” rating given on Tuesday, October 24 by Needham. On Friday, November 17 the stock rating was maintained by Argus Research with “Buy”. BMO Capital Markets maintained Cisco Systems, Inc. (NASDAQ:CSCO) on Thursday, August 17 with “Hold” rating. On Thursday, August 18 the stock rating was maintained by Drexel Hamilton with “Buy”. As per Thursday, November 16, the company rating was maintained by Nomura.

Analysts await Cisco Systems, Inc. (NASDAQ:CSCO) to report earnings on February, 21. They expect $0.53 earnings per share, 0.00% or $0.00 from last year’s $0.53 per share. CSCO’s profit will be $2.62 billion for 19.28 P/E if the $0.53 EPS becomes a reality. After $0.55 actual earnings per share reported by Cisco Systems, Inc. for the previous quarter, Wall Street now forecasts -3.64% negative EPS growth.

Investors sentiment decreased to 1.02 in Q3 2017. Its down 0.16, from 1.18 in 2017Q2. It turned negative, as 74 investors sold CSCO shares while 637 reduced holdings. 107 funds opened positions while 619 raised stakes. 3.60 billion shares or 0.03% more from 3.60 billion shares in 2017Q2 were reported. Heritage Mngmt holds 766,193 shares. Alta Capital Mngmt Limited Liability Co has invested 0.1% in Cisco Systems, Inc. (NASDAQ:CSCO). Federated Pa holds 0.14% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO) for 1.48M shares. Madrona Finance Service Limited Liability Co holds 0.26% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO) for 8,428 shares. Vanguard Grp Inc Inc reported 0.56% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO). Hamel stated it has 0.52% in Cisco Systems, Inc. (NASDAQ:CSCO). Clear Harbor Asset Mngmt Limited Liability Company owns 6,023 shares. Moreover, Canandaigua Natl Bank And has 0.45% invested in Cisco Systems, Inc. (NASDAQ:CSCO). Peapack Gladstone has invested 0.59% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO). Maple Cap Management holds 0.11% in Cisco Systems, Inc. (NASDAQ:CSCO) or 12,621 shares. Sol Capital Mgmt reported 0.54% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO). Edge Wealth Limited Com holds 358,200 shares. Foster Dykema Cabot & Inc Ma holds 0.09% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO) for 15,400 shares. Spinnaker Trust holds 0.68% of its portfolio in Cisco Systems, Inc. (NASDAQ:CSCO) for 162,139 shares. Signature Finance Mgmt has 0.22% invested in Cisco Systems, Inc. (NASDAQ:CSCO) for 23,386 shares.

Ulysses Management Llc increased Spdr S&P 500 Etf Tr (Put) (SPY) stake by 205,000 shares to 1.60 million valued at $401.97M in 2017Q3. It also upped Av Homes Inc (NASDAQ:AVHI) stake by 91,224 shares and now owns 638,977 shares. Powershares Qqq Trust (Put) (QQQ) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: